<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
SALT LAKE CITY , March 15, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock. “This share repurchase program is aligned with our commitment to return value to our shareholders and reflects confidence in our balance sheet and strong cash flow generation,” remarked Brian Brown, Chief Financial Officer of Co-Diagnostics.
...read full article on PRNewsWire
